Convergence Pharmaceuticals
Cambridge · Founded 2010
About Convergence Pharmaceuticals
Convergence Pharmaceuticals is an independent biotechnology company focused on the development of novel analgesics with potentially commercially attractive efficacy, responder-rate and side effect profiles. The Company was formed in October 2010 following the acquisition of certain neuroscience clinical assets from GlaxoSmithKline (“GSK“). Convergence Pharmaceuticals has a pipeline of differentiated clinical-stage compounds targeting the points of convergence in chronic pain signaling through modulation of specific ion-channels.
Company Facts
- Founded: 2010
- Legal name: CONVERGENCE PHARMACEUTICALS LIMITED
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $35.4M
- Funding stage: M&A
- Last round: Series A (Oct 2010)
- Website: convergencepharma.com
- Phone: 44 1223 755 501
Canonical: https://fsome.com/organization/convergence-pharmaceuticals-8406721 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.